Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ADX-324

Oligonucleotide (siRNA) · Gene silencing · developed by ADARx Pharmaceuticals

Phase 3 Most advanced trial

ADRX Developer

1 Registered trials

What is ADX-324?

ADX-324 is a siRNA duplex oligonucleotide in development for hereditary angioedema (HAE).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: siRNA
Drug type: Oligonucleotide (siRNA)
Mechanism: Gene silencing
Therapy area: Immunology
Developer: ADARx Pharmaceuticals, Inc. (ADRX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: T4XC2DH9BM

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07428499	Phase 3	Hereditary Angioedema (HAE)	Recruiting	ADRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HAEHereditary AngioedemaHereditary Angioedema - Type 1Hereditary Angioedema - Type 2Hereditary Angioedema (HAE)

More from ADARx Pharmaceuticals

ADX-038 Phase 1/2 ADX-626 Phase 1 ADX-850 Phase 1

Sources

ClinicalTrials.gov NCT06960213

Updated Oct 3, 2026. Something wrong or missing? Report it on the ADRX page.

Follow ADRX, the company behind ADX-324

See ADRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ADRX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z